Alzheimer's disease (AD) is a common neurodegenerative disease. With the aging of the global population, the number of patients with AD is constantly increasing, bringing heavy burdens to the patients, families and society. The early and accurate diagnosis of AD has always been a hot and difficult issue. In recent years, with the advancement of scientific research, there have been significant achievements in the study of imaging and biofluid biomarkers of AD, such as the new breakthroughs in PET imaging technology in detecting amyloid and Tau protein deposition in the brain, and the discovery and application of blood biomarkers among biofluid biomarkers. In 2024, The National Institute on Aging and Alzheimer's Association (NIA-AA) updated the diagnostic and staging guidelines for AD, namely the Revised Criteria for Diagnosis and Staging of Alzheimer's Disease (2024). This paper aims to interpret the guidelines and review the progress in the diagnosis and staging of AD, providing more accurate diagnostic basis for clinicians and helping researchers to further explore the pathogenesis of AD.